February 18, 2014 — HealthMed Holdings completed validation on a blood test that aims to identify individuals who are at risk of a heart attack and may be missed by conventional tests.
These individuals have no symptoms and frequently have normal standard blood cholesterol profiles, but are at significant risk of having a heart attack in the near term. The group is actively commercializing the test.
The MAP Test (Myocardial Assessment Profile) covers pathways involved in unstable cardiac lesions due to inflammation. Inflammation is the most common cause of heart attacks (up to 75 percent).
HealthMed Holdings Managing Partner, Douglas S. Harrington, M.D., said the test will be offered globally with a focus on nations where there has been a steep rise in cardiac disease, obesity and diabetes.
The MAP Test measures compounds in the blood associated with vascular inflammation causing unstable cardiac lesions. Measurement of these compounds in a person's serum enables identification of patients at risk of a heart attack in the near term. The MAP Test allows physicians to more effectively manage and treat their patients to the new ACC/AHA Cardiac guidelines, aiding in the reduction and prevention of cardiac events. Used in conjunction with other clinical information, the MAP Test's easy to understand results yield better compliance and behavioral changes by patients.